Gainers: ACST +16% . LXRX +13% . NQ +9% . USU +9% . AAL +6% . TXMD +5% . CAMT +5% . Losers: GIMO -33% . TCS -15% . PT -7% . Post your comment!
Lonnel Coats, most recently the head of Japanese pharma giant Eisai's U.S. unit, has been named Lexicon's ( LXRX ) new CEO, effective today. Coats' hiring comes 6 months after Lexicon announced (along with huge job cuts) CEO Arthur Sands is leaving. Post your comment!
background in cardiovascular disease and endocrinology, which is critical for the firm's LX4211 program. Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising
I guess I should address this to Morning Star but don't find a way. My question is how can you cover in analysis a stock such as LXRX with 149 employes and not cover in your analysis a stock such as HLS, makes me wonder about how you pick your stocks to analyse. Jack
Despite a pipeline, lexicon pharma does not look cheap. At a valuation today of nearly 900 million, and an expensive road to drug approval, we should all expect continuing dilution of this equity. To my mind, the only reason to invest is for a catalyst gap up. Their diabetes drug looks intriguing,
the criterion of "5 stars." I only got 6 stocks, none of them were familiar to me. Can this be right? Alumina AWCMY Buenaventure Mining BVN Fiat Group FIATY Lexicon Pharmaceuticals LXRX Petroleo Brasileiro SA Petrobras ADR BPR Posco PKX
Morningstar rating change from 4-5 Stars. Does anyone buy or sell, based on M rating changes?
Lexicon Pharmaceuticals announced that longtime CEO and cofounder Arthur Sands plans to depart the firm, and that it will cut 45% of its workforce
Lexicon Pharmaceuticals LXRX reported second-quarter results that put it on track to meet our forecast for the year, and we're maintaining our $3.50
Lexicon LXRX has released data from a Phase 2b study of LX4211, and we're maintaining our fair value estimate as we expect the firm to move